摘要
目的:研究多发性骨髓瘤早期肾损伤患者血清胱抑素C(Cys C)、肌酐(Cr)及乳酸脱氢酶(LDH)变化的价值,为临床诊断提供参考。方法:回顾性分析我院及西安交通大学第二附属医院于2016年1月至2018年1月期间收治的40例多发性骨髓瘤患者的临床资料作为观察组,另选取同期来院参加体检的健康志愿者40例作为对照组。对比两组受检者的血清Cys C、Cr及LDH水平,并分析其诊断及联合诊断特异度及灵敏度。结果:两组间相比,观察组患者的血清Cys C、Cr及LDH水平明显高于对照组,差异有统计学意义(P<0. 05)。两组间相比,观察组患者的血清Cys C、Cr及LDH阳性率分别为62. 5%、42. 5%、60. 0%,均高于对照组,差异有统计学意义(P <0. 05)。而诊断效能对比,Cys C、Cr及LDH三者联合检测的灵敏度最高,可达到95. 0%。结论:多发性骨髓瘤早期肾损伤患者血清Cys C、Cr及LDH水平及阳性率均明显升高,且三者联合诊断灵敏度最高,值得临床借鉴。
Objective To study the changes of serum cystatin C (CysC),creatinine (Cr) and lactate dehydrogenase (LDH) in patients with multiple myeloma at early stage of renal injury,so as to provide references for clinical diagnosis. Methods: The clinical data of 40 patients with multiple myeloma admitted to our hospital from January 2016 to January 2018 in our hospital were retrospectively analyzed,and 40 healthy volunteers in the same period were selected as control group.The serum levels of CysC,Cr and LDH were compared between the two groups,and the specificity and sensitivity of the diagnosis and joint diagnosis were analyzed. Results: Compared with the two groups,the levels of serum CysC,Cr and LDH in patients with multiple myeloma at early stage were significantly higher than those in the control group,the difference was statistically significant ( P 〈0.05).The positive rates of serum CysC,Cr and LDH in patients with multiple myeloma at early stage were 62.5%,42.5% and 60.0%,respectively,which were all higher than those in the control group ( P 〈0.05).In contrast,the sensitivity of combined detection of CysC,Cr and LDH three was the highest,which could reach 95.0%. Conclusion: The level of serum CysC,Cr and LDH and the positive rate of patients with multiple myeloma at early stage were significantly increased,and the combined diagnostic sensitivity of the three groups was the highest,which is worthy of clinical reference.
作者
宋斌
陈雁
张荣耀
李娜
耿伟
郭秀
张王刚
万楚成
Song Bin;Chen Yan;Zhang Rongyao;Li Na;Geng Wei;Guo Xiu;Zhang Wanggang;Wan Chucheng(Department of Hematology,Affiliated Taihe Hospital of Hubei Medical College,Hubei Shiyan 442000,China;Department of Hematology,The Second Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710004,China.)
出处
《现代肿瘤医学》
CAS
2018年第21期3471-3474,共4页
Journal of Modern Oncology
基金
湖北省十堰市科学技术研究与开发项目(编号:15Y18)